Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. reports developments as a life sciences and health-innovation platform with operating subsidiaries focused on diagnostics, precision oncology, and immune-system technologies. Company news includes updates on Ignite Proteomics, a commercial-stage precision oncology business that uses functional protein profiling to support cancer therapy selection, and Pearsanta, which is developing blood-based diagnostic tests including the Mitomic Endometriosis Test.
Recurring ADTX coverage also includes subsidiary leadership, clinical and research publications, acquisition activity, shareholder votes, reverse stock splits, Nasdaq listing matters, and other capital-structure actions tied to the company’s publicly traded common stock.
Aditxt Therapeutics, Inc. (Nasdaq: ADTX) has announced plans to file for Emergency Use Authorization (EUA) and a 510(k) application for its AditxtScore™ for COVID-19, a multiplex assay for detecting SARS-CoV-2 antibodies. Validated by Stanford Blood Center, this platform distinguishes various antibody isotypes (IgG, IgM, IgA) simultaneously, enhancing detection sensitivity. Aditxt aims for regulatory submissions by Q3 2020 and anticipates launching pilot programs in Q4 2020 and commercial availability in Q1 2021. The AditxtScore™ may also be used for evaluating immune responses to vaccines.
Aditx Therapeutics, Inc. (ADTX) will present virtually at the Zooming with LD event on July 28, 2020, at 11:00 AM ET. CEO Amro Albanna will lead the presentation, focusing on the company's efforts in immune system health through monitoring and reprogramming technologies. Interested participants can register to attend by accessing the provided link and selecting the date for the Zoom link. Aditx's technology aims to create personalized immune profiles and potentially retrain the immune system to combat organ rejection, autoimmune diseases, and allergies.
Aditxt Therapeutics has appointed Corinne Pankovcin as Chief Financial Officer, effective July 2, 2020. With 30 years of experience in public company finance, Pankovcin's previous roles include CFO at Business Development Corporation of America and BlackRock Capital Investment Corporation. Her expertise will support Aditxt's growth and strategic objectives. The company focuses on improving immune system health through innovative technologies. Pankovcin holds a Bachelor’s in Accounting and an MBA, and is a Certified Public Accountant.
Aditxt announced the conversion of approximately $1.1 million in accrued compensation for its CEO, Chief Innovation Officer, and two senior advisors into equity units. This conversion aligns with the terms of the company's recent IPO, completed on July 2, 2020, where 1,226,668 units were sold for about $11.0 million. Each unit included one share of common stock and two types of warrants, allowing further stock purchases at specified prices. The company's immune monitoring and reprogramming technologies aim to enhance the immune system's health.
Summary not available.
Aditxt Therapeutics, Inc. (Nasdaq: ADTX) has successfully closed its initial public offering, raising $11.0 million by issuing 1,226,668 units. Each unit comprises one share of common stock, and one Series A and Series B warrant. The Series A warrants are priced at $9.00 and will expire in five years, while Series B warrants have an exchange feature based on trading volume. The common stock began trading on June 30, 2020, on Nasdaq. The offering was managed by Dawson James Securities, with an option for underwriters to purchase up to an additional 184,000 shares.
Aditx Therapeutics has priced its initial public offering at $9.00 per unit, consisting of 1,226,668 units. Each unit includes one share of common stock, a Series A warrant, and a Series B warrant. The Series A warrants allow for purchase at $9.00, while the Series B warrants can be exercised at $11.25. The company has granted underwriters a 45-day option to purchase 184,000 additional units.
The shares will trade on Nasdaq under the ticker ADTX, beginning June 30, 2020. The company is focused on immune system technologies currently in the pre-clinical stage.